Key Drivers
- Strong Liquidity
- Rising Losses
- Negative Cash Flow
AIAI Summary
FLGT is a balance-sheet-backed turnaround trade—its deep discount to tangible book offers upside only if management reverses worsening margins and cash burn before losses materially erode its investment portfolio; investors should await clear evidence of stabilizing free cash flow and laboratory profitability.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Rising Losses
- •Negative Cash Flow
FLGT's strong, debt-light balance sheet and discount to tangible book provide downside support, but worsening losses and negative cash flow make operational turnaround the key catalyst.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Accelerating gains
- •Overbought momentum
FLGT's last-month uptrend remains bullish, but RSI near 74 and resistance at $21.85 suggest waiting for a breakout or pullback toward $21.28 support.
Rapid, consistent gains from 2026-09-09 to 2026-09-17 raise pullback risk
Sentiment & News
Key News Insights:
- •HSBC stake
- •45,048 shares
- •Modest ownership
- •News View: The filing is mildly supportive for FLGT sentiment but does not alter its operational or financial outlook.
HSBC initiated a 0.16% stake in Fulgent Genetics, signaling modest new institutional interest.
Similar Companies in Healthcare
Other companies in the same sector with AI ratings